Imprimis Phar Cmn (IMMY) 3.87 $IMMY
Imprimis Launches New MaxRx Prescriber Portal(TM)
PR Newswire - Fri Jul 29, 8:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced the availability of its new MaxRx Prescriber Portal(TM), a software application that provides physicians with new order entry and management tools that have traditionally not been available for compounded prescriptions. In addition to allowing a streamlined ordering process for single and multiple orders, MaxRx has numerous other functions designed to give the prescriber maximum visibility into order workflow, and maximum flexibility in communicating and doing business with an ImprimisRx pharmacy.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Present at 6th Annual LD Micro Invitational on June 8, 2016
PR Newswire - Fri Jun 03, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced that its Chief Financial Officer, Andrew R. Boll, will present an update on the company's business at the 6th Annual LD Micro Invitational on Wednesday, June 8, 2016 at 2:00 p.m. (PDT) in Bel Air, Calif. Imprimis will also be hosting one-on-one meetings and attendees can contact their LD Micro representative to arrange a meeting.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 3:30 p.m. (EDT) in New York City, NY. The presentation will be broadcast in a live webcast and an archive of the webcast will be available for 90 days following the event. Access will be available at http://wsw.com/webcast/jeff97/immy or on the Investor Relations section of Imprimis' website at www.ImprimisPharma.com. Imprimis will also be hosting one-on-one meetings and attendees can contact their Jefferies representative to arrange a meeting.
IMMY: 3.87 (-0.03)
Imprimis reports 1Q loss
Automated Insights - Thu May 12, 3:31PM CDT
SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Thursday reported a loss of $4.5 million in its first quarter.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Thu May 12, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today reported financial results for the first quarter 2016, and will provide an update on recent business developments on a conference call this afternoon.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Plans to Launch IV Free(TM) Conscious Sedation and New Compounded Triple Drop Formulations at Leading Cataract and Refractive Surgeons Meeting
PR Newswire - Thu May 05, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced plans to launch its IV Free(TM) MKO Melt(TM) conscious sedation formulations and new triple combination eye drop that includes nepafenac at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Host its First Quarter 2016 Financial Report Conference Call and Webcast on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Wed May 04, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today reported that it will release its first quarter 2016 financial results on Thursday, May 12, 2016. The company will host a conference call at 4:30 p.m. EDT (1:30 p.m. PDT) on the same day to discuss its financial results and report on recent business activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative to Thiola®
PR Newswire - Mon May 02, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced the availability of the company's new patent-pending customizable delayed-release (DR) tiopronin formulations as a lower-cost therapeutic alternative to FDA-approved Thiola®. Thiola, FDA-approved as a 100mg tablet, is composed of tiopronin as its sole active drug ingredient and is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. Physicians and their cystinuria patients may now choose from one of two lower-cost compounded alternatives to Thiola.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Registers its Texas Facility with the FDA as an Outsourcing Facility
PR Newswire - Tue Apr 12, 6:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, announced today that it has filed for registration of its ImprimisRx TX pharmacy, located in Allen, Texas, with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility. The Drug Quality and Security Act (DQSA), signed into law on November 27, 2013, created this pathway in which a compounding pharmacy can voluntarily register with the FDA as an outsourcing facility under Section 503B of the federal Food, Drug and Cosmetic Act, comply with the DQSA and avail itself of the operational benefits the law provides.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results and Provides Business Update
PR Newswire - Wed Mar 23, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today reported financial results for the fourth quarter and year ended December 31, 2015, and will provide an update on recent business developments on a conference call this afternoon.
IMMY: 3.87 (-0.03)
Investor Calendar Invites You to the Imprimis Pharmaceuticals Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Wednesday, March 23, 2016
ACCESSWIRE - Tue Mar 22, 3:05PM CDT
SAN DIEGO, CA / ACCESSWIRE / March 22, 2016 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Wednesday, March 23, 2016 at 4:30 PM Eastern Time.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Host its Fourth Quarter and Fiscal Year 2015 Financial Report Conference Call and Webcast on March 23, 2016 at 4:30 p.m. EDT
PR Newswire - Thu Mar 17, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today reported that it will release its fourth quarter and fiscal year 2015 financial results on Wednesday, March 23, 2016. The company will host a conference call at 4:30 p.m. EDT (1:30 p.m. PDT) on the same day to discuss its financial results and report on recent business activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
PR Newswire - Wed Mar 16, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ("Imprimis" or the "company"
, a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, announced today that it has completed the previously announced public offering of common stock. Imprimis sold 2.9 million shares in the offering and an additional 435,000 common shares upon the full exercise by the underwriters of their over-allotment option. The offering price was $3.60 per share, and the gross proceeds to Imprimis from the sale of shares, including the over-allotment option, were $12 million, before deducting underwriting expenses.
NHLD: 3.02 (-0.08), IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PR Newswire - Fri Mar 11, 7:45AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ("Imprimis" or the "company" , a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, announced today the pricing of an underwritten public offering of 2.9 million shares of its common stock at a price to the public of $3.60 per share, before underwriting discounts. In addition, the company has granted the underwriters the option, exercisable for 45 days, to purchase an additional 435,000 shares of its common stock to cover over-allotments. The offering is expected to close on or about March 16, 2016, subject to satisfaction of customary closing conditions.
NHLD: 3.02 (-0.08), IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Proposed Public Offering of Common Stock
PR Newswire - Thu Mar 10, 3:05PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ("Imprimis" or the "company" , a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, announced today a proposed underwritten public offering of its common stock, subject to market and other conditions. In connection with the offering, the company intends to grant the underwriters the option, exercisable for 45 days, to purchase additional shares equal to up to 15% of the aggregate number of shares sold in the offering to cover over-allotments.
NHLD: 3.02 (-0.08), IMMY: 3.87 (-0.03)
Statement on Imprimis Pharmaceuticals' Announcement Regarding Thiola(R)
GlobeNewswire - Wed Feb 10, 12:28PM CST
Retrophin, Inc. (NASDAQ:RTRX) has issued the following statement in response to Imprimis Pharmaceuticals' announcement of its intention to make a compounded alternative to Thiola:
RTRX: 17.93 (+0.40), IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Make a Lower Cost Compounded and Customizable Alternative to Thiola®
PR Newswire - Wed Feb 10, 8:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced plans to introduce new patent-pending tiopronin and potassium citrate delayed release (DR) compounded formulations that may be prescribed by physicians as a lower cost therapeutic alternative to FDA-approved Thiola. The formulations are expected to be available to prescribers in April 2016. Thiola, made of tiopronin as its active drug ingredient, is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. According to the National Organization for Rare Disorders, in addition to chelating medications such as tiopronin, potassium citrate is often co-prescribed and taken separately to make the urine more alkaline, potentially reducing cystine crystallization and stone formation.
IMMY: 3.87 (-0.03)
Express Scripts Provides Better-than-Expected 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:40PM CST
Express Scripts Holding Company (ESRX) has issued an encouraging guidance for 2016.
ANTM: 131.34 (-1.56), ESRX: 76.07 (-1.02), UNH: 143.20 (+0.44), IMMY: 3.87 (-0.03)
Global Peyronies Disease Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 8:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcx4vk/peyronies_disease) has announced the addition of the "Peyronies Disease Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Peyronies Disease Global Clinical Trials Review, H2, 2015" provides an overview of Peyronies Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Peyronies Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Endo International Plc - Dimensione Ricerca S.r.l. (Inactive) - Allergan Plc - TFS International AB - Men's Health Boston - Imprimis Pharmaceuticals, Inc. - Hybrid Medical, LLC For more information visit http://www.researchandmarkets.com/research/zc...es_disease
AGN: 252.95 (-2.61), IMMY: 3.87 (-0.03)
Imprimis Launches New MaxRx Prescriber Portal(TM)
PR Newswire - Fri Jul 29, 8:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced the availability of its new MaxRx Prescriber Portal(TM), a software application that provides physicians with new order entry and management tools that have traditionally not been available for compounded prescriptions. In addition to allowing a streamlined ordering process for single and multiple orders, MaxRx has numerous other functions designed to give the prescriber maximum visibility into order workflow, and maximum flexibility in communicating and doing business with an ImprimisRx pharmacy.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Present at 6th Annual LD Micro Invitational on June 8, 2016
PR Newswire - Fri Jun 03, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced that its Chief Financial Officer, Andrew R. Boll, will present an update on the company's business at the 6th Annual LD Micro Invitational on Wednesday, June 8, 2016 at 2:00 p.m. (PDT) in Bel Air, Calif. Imprimis will also be hosting one-on-one meetings and attendees can contact their LD Micro representative to arrange a meeting.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 3:30 p.m. (EDT) in New York City, NY. The presentation will be broadcast in a live webcast and an archive of the webcast will be available for 90 days following the event. Access will be available at http://wsw.com/webcast/jeff97/immy or on the Investor Relations section of Imprimis' website at www.ImprimisPharma.com. Imprimis will also be hosting one-on-one meetings and attendees can contact their Jefferies representative to arrange a meeting.
IMMY: 3.87 (-0.03)
Imprimis reports 1Q loss
Automated Insights - Thu May 12, 3:31PM CDT
SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Thursday reported a loss of $4.5 million in its first quarter.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Thu May 12, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding(TM) business model, today reported financial results for the first quarter 2016, and will provide an update on recent business developments on a conference call this afternoon.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Plans to Launch IV Free(TM) Conscious Sedation and New Compounded Triple Drop Formulations at Leading Cataract and Refractive Surgeons Meeting
PR Newswire - Thu May 05, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced plans to launch its IV Free(TM) MKO Melt(TM) conscious sedation formulations and new triple combination eye drop that includes nepafenac at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Host its First Quarter 2016 Financial Report Conference Call and Webcast on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Wed May 04, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today reported that it will release its first quarter 2016 financial results on Thursday, May 12, 2016. The company will host a conference call at 4:30 p.m. EDT (1:30 p.m. PDT) on the same day to discuss its financial results and report on recent business activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative to Thiola®
PR Newswire - Mon May 02, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced the availability of the company's new patent-pending customizable delayed-release (DR) tiopronin formulations as a lower-cost therapeutic alternative to FDA-approved Thiola®. Thiola, FDA-approved as a 100mg tablet, is composed of tiopronin as its sole active drug ingredient and is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. Physicians and their cystinuria patients may now choose from one of two lower-cost compounded alternatives to Thiola.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Registers its Texas Facility with the FDA as an Outsourcing Facility
PR Newswire - Tue Apr 12, 6:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, announced today that it has filed for registration of its ImprimisRx TX pharmacy, located in Allen, Texas, with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility. The Drug Quality and Security Act (DQSA), signed into law on November 27, 2013, created this pathway in which a compounding pharmacy can voluntarily register with the FDA as an outsourcing facility under Section 503B of the federal Food, Drug and Cosmetic Act, comply with the DQSA and avail itself of the operational benefits the law provides.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results and Provides Business Update
PR Newswire - Wed Mar 23, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today reported financial results for the fourth quarter and year ended December 31, 2015, and will provide an update on recent business developments on a conference call this afternoon.
IMMY: 3.87 (-0.03)
Investor Calendar Invites You to the Imprimis Pharmaceuticals Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Wednesday, March 23, 2016
ACCESSWIRE - Tue Mar 22, 3:05PM CDT
SAN DIEGO, CA / ACCESSWIRE / March 22, 2016 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Wednesday, March 23, 2016 at 4:30 PM Eastern Time.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Host its Fourth Quarter and Fiscal Year 2015 Financial Report Conference Call and Webcast on March 23, 2016 at 4:30 p.m. EDT
PR Newswire - Thu Mar 17, 7:30AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today reported that it will release its fourth quarter and fiscal year 2015 financial results on Wednesday, March 23, 2016. The company will host a conference call at 4:30 p.m. EDT (1:30 p.m. PDT) on the same day to discuss its financial results and report on recent business activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
PR Newswire - Wed Mar 16, 3:05PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ("Imprimis" or the "company"
, a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, announced today that it has completed the previously announced public offering of common stock. Imprimis sold 2.9 million shares in the offering and an additional 435,000 common shares upon the full exercise by the underwriters of their over-allotment option. The offering price was $3.60 per share, and the gross proceeds to Imprimis from the sale of shares, including the over-allotment option, were $12 million, before deducting underwriting expenses. NHLD: 3.02 (-0.08), IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PR Newswire - Fri Mar 11, 7:45AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ("Imprimis" or the "company"
, a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, announced today the pricing of an underwritten public offering of 2.9 million shares of its common stock at a price to the public of $3.60 per share, before underwriting discounts. In addition, the company has granted the underwriters the option, exercisable for 45 days, to purchase an additional 435,000 shares of its common stock to cover over-allotments. The offering is expected to close on or about March 16, 2016, subject to satisfaction of customary closing conditions. NHLD: 3.02 (-0.08), IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals Announces Proposed Public Offering of Common Stock
PR Newswire - Thu Mar 10, 3:05PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ("Imprimis" or the "company"
, a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, announced today a proposed underwritten public offering of its common stock, subject to market and other conditions. In connection with the offering, the company intends to grant the underwriters the option, exercisable for 45 days, to purchase additional shares equal to up to 15% of the aggregate number of shares sold in the offering to cover over-allotments. NHLD: 3.02 (-0.08), IMMY: 3.87 (-0.03)
Statement on Imprimis Pharmaceuticals' Announcement Regarding Thiola(R)
GlobeNewswire - Wed Feb 10, 12:28PM CST
Retrophin, Inc. (NASDAQ:RTRX) has issued the following statement in response to Imprimis Pharmaceuticals' announcement of its intention to make a compounded alternative to Thiola:
RTRX: 17.93 (+0.40), IMMY: 3.87 (-0.03)
Imprimis Pharmaceuticals to Make a Lower Cost Compounded and Customizable Alternative to Thiola®
PR Newswire - Wed Feb 10, 8:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced plans to introduce new patent-pending tiopronin and potassium citrate delayed release (DR) compounded formulations that may be prescribed by physicians as a lower cost therapeutic alternative to FDA-approved Thiola. The formulations are expected to be available to prescribers in April 2016. Thiola, made of tiopronin as its active drug ingredient, is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. According to the National Organization for Rare Disorders, in addition to chelating medications such as tiopronin, potassium citrate is often co-prescribed and taken separately to make the urine more alkaline, potentially reducing cystine crystallization and stone formation.
IMMY: 3.87 (-0.03)
Express Scripts Provides Better-than-Expected 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:40PM CST
Express Scripts Holding Company (ESRX) has issued an encouraging guidance for 2016.
ANTM: 131.34 (-1.56), ESRX: 76.07 (-1.02), UNH: 143.20 (+0.44), IMMY: 3.87 (-0.03)
Global Peyronies Disease Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 8:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcx4vk/peyronies_disease) has announced the addition of the "Peyronies Disease Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Peyronies Disease Global Clinical Trials Review, H2, 2015" provides an overview of Peyronies Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Peyronies Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Endo International Plc - Dimensione Ricerca S.r.l. (Inactive) - Allergan Plc - TFS International AB - Men's Health Boston - Imprimis Pharmaceuticals, Inc. - Hybrid Medical, LLC For more information visit http://www.researchandmarkets.com/research/zc...es_disease
AGN: 252.95 (-2.61), IMMY: 3.87 (-0.03)
